Boc-MLF TFA
Based on 4 publication(s) in Google Scholar
Boc-MLF TFA (Boc-Met-Leu-Phe-OH TFA) is a competitive FPR1 antagonist. Boc-MLF TFA inhibits fMLF-induced neutrophil activation through FPR. Boc-MLF TFA inhibits receptor-induced inflammation and cell migration. Boc-MLF TFA inhibits amniotic epithelial-mesenchymal transition. Boc-MLF TFA reduces pro-inflammatory cytokine levels. Boc-MLF TFA increases collagen expression in fetal membranes. Boc-MLF TFA reverses fetal membrane epithelial cell collapse, increases villi, and reduces mucus attachment. Boc-MLF TFA can be used in research on premature rupture of fetal membranes.
For research use only. We do not sell to patients.
- Purity : 99.48%
- Formula: C27H40F3N3O8S
- Molecular Weight:623.68
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Boc-MLF TFA
More
Biological Activity
Description
In Vitro
Boc-MLF TFA acts as a fairly specific FPR antagonist in human neutrophils, inhibiting fMLF-induced NADPH oxidase activity while only slightly affecting WKYMVM-induced activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (female; pregnant; 6 months old; 15-17 days gestation; 250-350 g)[2]
-
Dosage:5 mg/kg
-
Administration:intraperitoneal injection; once daily; 2 consecutive days
-
Result:In the LPS+BOC-MLF group, FPR1 expression in fetal membranes was decreased compared with the LPS group.
IL-6 levels in cardiac blood were decreased compared with the LPS group.
EMT was reversed compared with the LPS group, with changes in E-Cad and Vimentin expression opposite to those in the LPS group.
Collagen expression in fetal membranes was increased compared with the LPS group.
Scanning electron microscopy showed reversal of LPS effects, with slight plumping of fetal membrane epithelial cells, increased villi, and no obvious mucus.
- Phagocytosis Functional Assay
- Scratch/Wound-Healing Migration Assay
- RNA extraction experimental
- Cell migration
- Chemotaxis Gradient Chamber Assay 1
- Under-Agarose Cell Migration Assay
- Neural Crest/Neuronal Cell Migration Explant Assay
- Transwell/Boyden Chamber Migration Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- Research Protocol for Inflammation-related Diseases
- Cell-Exclusion Zone Migration Assay
- Chemotaxis Gradient Chamber Assay 2
Chemical Information
-
Appearance Solid
-
Molecular Weight 623.68
-
Formula C27H40F3N3O8S
-
Color White to off-white
-
SMILES
O=C(O)[C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@H](CCSC)NC(OC(C)(C)C)=O)=O)=O.OC(C(F)(F)F)=O
-
Synonyms
Boc-Met-Leu-Phe-OH TFA
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
World J Gastroenterol
Mechanism of annexin A1/N-formylpeptide receptor regulation of macrophage function to inhibit hepatic stellate cell activation through Wnt/β-catenin pathway. [Abstract]2023 Jun 14;29(22):3422-3439. PMID: 37389234 -
iScience
2023 Oct 6;26(11):108153. PMID: 37867938 -
Immunol Lett
Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. [Abstract]2026 Apr:278:107122. PMID: 41349809 -
Solvent & Solubility
In Vitro:
DMSO : 150 mg/mL (240.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6034 mL | 8.0169 mL | 16.0339 mL | 40.0847 mL |
| 5 mM | 0.3207 mL | 1.6034 mL | 3.2068 mL | 8.0169 mL | |
| 10 mM | 0.1603 mL | 0.8017 mL | 1.6034 mL | 4.0085 mL | |
| 15 mM | 0.1069 mL | 0.5345 mL | 1.0689 mL | 2.6723 mL | |
| 20 mM | 0.0802 mL | 0.4008 mL | 0.8017 mL | 2.0042 mL | |
| 25 mM | 0.0641 mL | 0.3207 mL | 0.6414 mL | 1.6034 mL | |
| 30 mM | 0.0534 mL | 0.2672 mL | 0.5345 mL | 1.3362 mL | |
| 40 mM | 0.0401 mL | 0.2004 mL | 0.4008 mL | 1.0021 mL | |
| 50 mM | 0.0321 mL | 0.1603 mL | 0.3207 mL | 0.8017 mL | |
| 60 mM | 0.0267 mL | 0.1336 mL | 0.2672 mL | 0.6681 mL | |
| 80 mM | 0.0200 mL | 0.1002 mL | 0.2004 mL | 0.5011 mL | |
| 100 mM | 0.0160 mL | 0.0802 mL | 0.1603 mL | 0.4008 mL |
Boc-MLF TFA Related Classifications
HY-103473A Related Classifications
Powered by Bioz